Abstract
Clinical application of anti-tumor polymeric micellar drugs consisted with nanoparticles is on going. NC-6004 is cisplatin-incorporated micellar drug. The particle size of NC-6004 is small, which is approximately 30 nm. The particles are retained in blood flow a long time and sustain release of cisplatin. In terms of these characteristics, NC-6004 is expected to reduce the renal toxicity that is considered as one of the clinical issues of cisplatin therapy. NC-6004 is also expected to facilitate accumulation of cisplatin into tumor tissues by getting through pores in blood vessels of tumor tissues.
Phase I study of NC-6004 in patients with advanced cancer was conducted in UK. The results for the study were reviewed.
